TY - JOUR
T1 - Prognostic value of PET-CT after fi rst-line therapy in patients with follicular lymphoma
T2 - A pooled analysis of central scan review in three multicentre studies
AU - Trotman, Judith
AU - Luminari, Stefano
AU - Boussetta, Sami
AU - Versari, Annibale
AU - Dupuis, Jehan
AU - Tychyj, Christelle
AU - Marcheselli, Luigi
AU - Berriolo-Riedinger, Alina
AU - Franceschetto, Antonella
AU - Julian, Anne
AU - Ricard, Fabien
AU - Guerra, Luca
AU - Haioun, Corinne
AU - Biasoli, Irene
AU - Tilly, Hervé
AU - Federico, Massimo
AU - Salles, Gilles
AU - Meignan, Michel
PY - 2014
Y1 - 2014
N2 - Background: The value of 18F-fl uorodeoxyglucose (FDG) PET-CT (PET) imaging in response assessment after fi rst-line rituximab chemotherapy for follicular lymphoma has been documented. We analysed the application of the fi ve-point Deauville scale (5PS; used to score FDG uptake on PET images) in a large cohort derived from three studies, to assess the correlation between post-induction PET status and survival in patients with follicular lymphoma. Methods: In this pooled analysis, we used data from three multicentre prospective studies of fi rst-line rituximab chemotherapy for patients with high-tumour-burden follicular lymphoma (the PRIMA study, the PET-Folliculaire study, and the Fondazione Italiana Linfomi FOLL05 study). Patients included in this analysis received at least six cycles of rituximab and chemotherapy before response assessment with conventional contrast-enhanced CT and PET low-dose CT (PET). We included only patients who had a PET scan within 3 months of the last dose of induction rituximab. Patient data, including conventional CT-based response assessment, were recorded for all patients undergoing PET review. Scans undergoing central PET review were scored independently by three reviewers according to the 5PS. The primary endpoints were progression-free survival and overall survival according to the 5PS score of post-induction PET scan (ie, positive [≥4 points] or negative [
AB - Background: The value of 18F-fl uorodeoxyglucose (FDG) PET-CT (PET) imaging in response assessment after fi rst-line rituximab chemotherapy for follicular lymphoma has been documented. We analysed the application of the fi ve-point Deauville scale (5PS; used to score FDG uptake on PET images) in a large cohort derived from three studies, to assess the correlation between post-induction PET status and survival in patients with follicular lymphoma. Methods: In this pooled analysis, we used data from three multicentre prospective studies of fi rst-line rituximab chemotherapy for patients with high-tumour-burden follicular lymphoma (the PRIMA study, the PET-Folliculaire study, and the Fondazione Italiana Linfomi FOLL05 study). Patients included in this analysis received at least six cycles of rituximab and chemotherapy before response assessment with conventional contrast-enhanced CT and PET low-dose CT (PET). We included only patients who had a PET scan within 3 months of the last dose of induction rituximab. Patient data, including conventional CT-based response assessment, were recorded for all patients undergoing PET review. Scans undergoing central PET review were scored independently by three reviewers according to the 5PS. The primary endpoints were progression-free survival and overall survival according to the 5PS score of post-induction PET scan (ie, positive [≥4 points] or negative [
UR - http://www.scopus.com/inward/record.url?scp=84922032387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922032387&partnerID=8YFLogxK
U2 - 10.1016/S2352-3026(14)70008-0
DO - 10.1016/S2352-3026(14)70008-0
M3 - Article
AN - SCOPUS:84922032387
VL - 1
SP - e17-e27
JO - The Lancet Haematology
JF - The Lancet Haematology
SN - 2352-3026
IS - 1
ER -